OVID
Ovid Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OVID
Ovid Therapeutics Inc.
A biopharmaceutical company that develops medicines designed to conquer epilepsies
441 Ninth Avenue, 14th Floor, New York, New York 10001
--
Ovid Therapeutics Inc., was incorporated on April 1, 2014 under the laws of the State of Delaware. The company is a biopharmaceutical company focused on developing impactful drugs for patients and families with rare neurological diseases. The company believes that these diseases are an attractive area for drug development because the understanding of underlying biology has grown meaningfully over the past few years; but it is still ignored by the industry. Its experienced team has embarked on a vision of integrating the biology and symptoms of rare neurology, employing innovative research and clinical strategies for the development of its drug candidates. Using the latest scientific advances in genetics and biological pathways in the brain, the company has created a blueprint for disease-related pathways to identify and acquire new compounds for the treatment of rare neurological diseases. The company is executing its strategy to partner with leading biopharmaceutical companies and academic institutions in the licensing field. The company is developing a strong pipeline of clinical assets with an initial focus on neurodevelopmental disorders and rare epileptic encephalopathy.
Company Financials
EPS
OVID has released its 2025 Q3 earnings. EPS was reported at -0.17, versus the expected -0.15, missing expectations. The chart below visualizes how OVID has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
OVID has released its 2025 Q3 earnings report, with revenue of 132.00K, reflecting a YoY change of -23.70%, and net profit of -12.16M, showing a YoY change of 13.19%. The Sankey diagram below clearly presents OVID's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
